Keytruda (pembrolizumab) v indikácii ca žalúdka podľa klinického skúšania KN859

Organisation: Merck Sharp & Dohme, s.r.o.

Created at: 26.03.2025

Processed at: 02.04.2026

Question

Please include Keytruda (pembrolizumab) in the indication ca stomach and GEJ in the case of a final decision of the Ministry of Health of the Slovak Republic from 1.1.2026 in the DRG as an attributable item.

NA - Keytruda (pembrolizumab) is pending ID35514 in the indication in question

patients with HER2-negative gastric cancer and GEJ requiring first-line treatment for locally advanced, unresectable or metastatic cancer during hospitalisation according to the above IO

Answer

The indication restrictions (IOs) in the DRG system are aligned with the IOs that are listed in the categorisation list of medicines. As the SK-DRG system is updated only once a year and new indications enter the categorisation list all year round, in order to avoid misalignment of the two systems, the reporting of indication restrictions has been transferred to marker reporting, which makes the DRG system more flexible and as soon as a medicine is categorised under a new indication, it can also be reported under the DRG system.